Breaking news

Pfizer expects results from its coronavirus vaccine trials by October, CEO ...

Pfizer Inc says it could have results from its late-stage coronavirus vaccine trial available as early as October. 

On Thursday, CEO Albert Bourla said during a call sponsored by drug industry group International Federation of Pharmaceutical Manufacturers & Associations that  23,000 volunteers have been enrolled in the phase III trial, which began in July. 

The New York-based drug company says if data shows the jab is safe and effective, it will submit an application for approval, along with its German partner BioNTech, immediately.

'We expect by the end of October, we should have enough...to say whether the product works or not,' Bourla said.

Pfizer is in a race with companies such as AstraZeneca Plc, Johnson & Johnson, Moderna and Sanofi to produce a vaccine as President Donald pledged his administration could have an inoculation before the November 3 election. 

However, the White House fervently denied that anyone from the administration is putting political pressure on the US Food and Drug Administration to approve a vaccine.

Pfizer Inc has enrolled 23,000 people in phase III of its coronavirus vaccine trial, which began in July. Pictured: The first patient enrolled in Pfizer's coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection, May 2020

Pfizer Inc has enrolled 23,000 people in phase III of its coronavirus vaccine trial, which began in July. Pictured: The first patient enrolled in Pfizer's coronavirus vaccine clinical trial at the University of Maryland School of Medicine in Baltimore, receives an injection, May 2020

If the vaccine is shown to be safe and effective, CEO Albert Bourla says the company will apply for approval immediately. Pictured: Pfizer headquarters in New York City, July 2019

If the vaccine is shown to be safe and effective, CEO Albert Bourla says the company will apply for approval immediately. Pictured: Pfizer headquarters in New York City, July 2019 

The vaccine candidate from Pfizer and BioNTech uses part of the pathogen's genetic code called messenger RNA, or mRNa.

It trains the body to recognize the coronavirus, which will send out an immune response if a person becomes infected.

In July, the company released data from its early-stage trial, involving 45 people who received either a low, medium or high dose of the vaccine in two shots or a placebo.

Volunteers given either the low or medium

read more from dailymail.....

PREV How coronavirus hijacks the body and 'opens the floodgates' for mass infection
NEXT NHS enrolls 5,000 patients in mass trial of its soups and shakes diet to ...